Trial Profile

Feasibility study of fertility preservation before neoadjuvant or adjuvant chemotherapy for breast cancer: PRESAGE

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 11 Jan 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tamoxifen (Primary) ; Follicle stimulating hormones
Indications Breast cancer
Focus Therapeutic Use
Acronyms PRESAGE

Most Recent Events

11 Jan 2018 New trial record
09 Dec 2017 Results (n=50) assessing feasibility study of fertility preservation by controlled ovarian stimulation (COS) combined with Tamoxifene and oocyte +/- embryo cryopreservation before neoadjuvant (NAC) or adjuvant (AC) chemotherapy for breast cancer, were presented at the 40th Annual San Antonio Breast Cancer Symposium.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com